scholarly journals Peripheral T-Cell Lymphoma: Review and Updates of Current Management Strategies

2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Tiffany Tang ◽  
Kevin Tay ◽  
Richard Quek ◽  
Miriam Tao ◽  
Soo Yong Tan ◽  
...  
Keyword(s):  
T Cell ◽  
Nk Cell ◽  
Management Strategies ◽  
Disease Diagnosis ◽  
Epidemiological Studies ◽  
World Health ◽  
T Cell Lymphomas ◽  
Health Organization ◽  
Low Prevalence

The classification of T-cell and natural-killer- (NK-) cell lymphomas has been updated in the 4th edition of the World Health Organization (WHO) classification of tumors of the haematopoietic and lymphoid tissue published in 2008. Based on recent epidemiological studies, NK-cell lymphomas occur almost exclusively in Asia and South America, although T-cell lymphomas appear to occur in the East as commonly as in the West. Due to the low prevalence of this disease, diagnosis and optimal treatment of patients have not been studied prospectively in large randomized trials. Nevertheless, there has been development in the understanding of T-cell lymphomas and how they should be managed; FDG-PET emerges as an increasingly important tool in diagnosis, gene-expression signatures may aid with prognostication in the future, and novel therapies are currently being studied to improve outcomes in T-cell lymphomas. More work, however, needs to be done, and international collaboration will be pertinent to deriving meaningful results from future clinical studies.

scholarly journals Primary Cutaneous Acral CD8+ T-Cell Lymphoma

2017 ◽  
Vol 141 (11) ◽  
pp. 1469-1475 ◽  
Author(s):  
Vivian M. Hathuc ◽  
Alexandra C. Hristov ◽  
Lauren B. Smith
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Correct Diagnosis ◽  
Cd8 T Cell ◽  
T Cell Lymphoma ◽  
World Health ◽  
T Cell Lymphomas ◽  
Pathologic Features ◽  
Health Organization

Primary cutaneous acral CD8+ T-cell lymphoma is a new provisional entity in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. This is a challenging diagnosis because of its rarity, as well as its morphologic and immunophenotypic overlap with other CD8+ cytotoxic lymphoid proliferations. Appropriate classification of this entity is crucial because of its indolent clinical behavior compared with other CD8+ T-cell lymphomas. Knowledge of the clinical setting, sites of involvement, and morphologic features can aid in correct diagnosis. Here, we review the clinical and pathologic features of primary cutaneous acral CD8+ T-cell lymphoma with an emphasis on the differential diagnosis among other C8+ T-cell lymphomas.

scholarly journals Update on Gastrointestinal Lymphomas

2018 ◽  
Vol 142 (11) ◽  
pp. 1347-1351 ◽  
Author(s):  
Steven C. Weindorf ◽  
Lauren B. Smith ◽  
Scott R. Owens
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
World Health ◽  
Barr Virus ◽  
Not Otherwise Specified ◽  
Gastrointestinal Lymphomas ◽  
Epstein Barr ◽  
Health Organization

Herein we review the following selection of gastrointestinal lymphomas: monomorphic epitheliotropic intestinal T-cell lymphoma; indolent T-cell lymphoproliferative disorder of the gastrointestinal tract; intestinal T-cell lymphoma, not otherwise specified; duodenal-type follicular lymphoma; and Epstein-Barr virus–positive mucocutaneous ulcer. Definitions reflect the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Clinical, morphologic, and immunophenotypic characteristics of each entity are emphasized.

scholarly journals Uncommon Variants of Mature T-Cell Lymphomas (MTCLs): Imaging and Histopathologic and Clinical Features with Updates from the Fourth Edition of the World Health Organization (WHO) Classification of Lymphoid Neoplasms

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5217
Author(s):  
Ahmed Ebada Salem ◽  
Yehia H. Zaki ◽  
Gamal El-Hussieny ◽  
Khaled I. ElNoueam ◽  
Akram M. Shaaban ◽  
...  
Keyword(s):  
T Cell ◽  
Molecular Biology ◽  
Who Classification ◽  
Rare Variants ◽  
World Health ◽  
Complex Nature ◽  
Imaging Features ◽  
Fourth Edition ◽  
T Cell Lymphomas

Understanding the pathogenesis and molecular biology of malignant lymphomas is challenging, given the complex nature and incongruity of these disorders. The classification of lymphoma is continually evolving to account for advances in clinical, pathological, molecular biology and cytogenetic aspects, which impact our understanding of these disorders. The latest fourth edition of the WHO classification of lymphoid malignancies was released in 2016 to account for these changes. Additionally, unlike B-cell lymphomas (BCL), T-cell lymphomas (TCL) are uncommon, and may be sporadically experienced in clinical practice. These disorders are rare, thus early diagnosis is challenging for both physicians and radiologists, owing to the overlap in clinical and imaging features with other, more common disorders. We aim to discuss some rare variants of T-cell lymphomas, including clinicopathologic and imaging features, as well as to give a glimpse of the updates contained within the new 2016 WHO classification.

scholarly journals Pax5 as a potential candidate marker for canine B-cell lymphoma

2017 ◽  
Vol 62 (No. 2) ◽  
pp. 74-80
Author(s):  
S. Sirivisoot ◽  
S. Techangamsuwan ◽  
S. Tangkawattana ◽  
A. Rungsipipat
Keyword(s):  
T Cell ◽  
B Cell ◽  
Protein A ◽  
B Cell Lymphoma ◽  
World Health ◽  
Potential Candidate ◽  
Histopathological Classification ◽  
Cell Identification ◽  
T Cell Lymphomas ◽  
Health Organization

Immunophenotyping is a valuable method for prognosis in canine malignant lymphoma. The general B-cell marker is CD79a; however, Pax5 or B-cell specific activator protein, a transcription factor that controls B-cell identity and cell maturation, could also be used as a B-cell indicator in canine lymphomas. This study aimed to use Pax5, CD79a and CD3 expression in immunohistochemistry of spontaneous canine lymphomas, in order to carry out diagnosis and histopathological classification according to the World Health Organization guidelines. Forty-six retrospective cases including 33 multicentric, eight extranodal, and five alimentary lymphomas in dogs were immunostained by anti-Pax5 and anti-CD79a antibodies for B-cell identification, and anti-CD3 antibody for T-cell identification. T-cell lymphomas (CD3+/Pax5–/CD79a–) accounted for 30.43% of cases (14/46), and four of the lymphomas (28.57%) presented with CD3+/Pax5–/CD79a+. Conversely, B-cell lymphomas (CD3–/Pax5+/CD79a+) accounted for 69.57% of cases (32/46) and 12.5% of these (4/32) showed only Pax5-positive cells (CD3–/Pax5+/CD79a–). Therefore, in dogs, Pax5 appears to be a more useful marker for staining all B-cell subtypes compared to CD79a. Immunophenotyping with both Pax5 and CD3 are necessary for lymphoid lineage identification in canine lymphomas.

Global prevalence of chronic migraine: A systematic review

Cephalalgia ◽  
2009 ◽  
Vol 30 (5) ◽  
pp. 599-609 ◽  
Author(s):  
JL Natoli ◽  
A Manack ◽  
B Dean ◽  
Q Butler ◽  
CC Turkel ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Epidemiological Studies ◽  
Population Based ◽  
World Health ◽  
Future Studies ◽  
And Gender ◽  
Health Organization ◽  
Consensus Diagnosis ◽  
Incomplete Picture

The aim of this review was to summarize population-based studies reporting prevalence and/or incidence of chronic migraine (CM) and to explore variation across studies. A systematic literature search was conducted. Relevant data were abstracted and estimates were subdivided based on the criteria used in each study. Sixteen publications representing 12 studies were accepted. None presented data on CM incidence. The prevalence of CM was 0–5.1%, with estimates typically in the range of 1.4–2.2%. Seven studies used Silberstein–Lipton criteria (or equivalent), with prevalence ranging from 0.9% to 5.1%. Three estimates used migraine that occurred ≥ 15 days per month, with prevalence ranging from 0 to 0.7%. Prevalence varied by World Health Organization region and gender. This review identified population-based studies of CM prevalence, although heterogeneity across studies and lack of data from certain regions leaves an incomplete picture. Future studies on CM would benefit from an International Classification of Headache Disorders consensus diagnosis that is clinically appropriate and operational in epidemiological studies.

Lymphoma of the Skin

Hematology ◽  
2002 ◽  
Vol 2002 (1) ◽  
pp. 263-282 ◽  
Author(s):  
Joseph M. Connors ◽  
Eric D. Hsi ◽  
Francine M. Foss
Keyword(s):  
T Cell ◽  
Classification Scheme ◽  
Cell Lymphoma ◽  
Large Cell ◽  
World Health ◽  
T Cell Lymphomas ◽  
Cutaneous Lymphomas ◽  
Health Organization ◽  
Hodgkin's Lymphomas ◽  
Lymphoma Classification

Abstract This chapter describes the various ways in which the non-Hodgkin’s lymphomas can involve the skin, how these diseases should be assessed, standard treatments available in 2002, and new directions in research. The goal of the session is to succinctly review recent developments in lymphoma classification and treatment as they apply to the unique aspects of lymphoma when manifest in the skin. In Section I, Dr. Eric Hsi reviews the special characteristics of the lymphomas seen when they proliferate in the skin and the application of the new World Health Organization classification system to the cutaneous lymphomas, emphasizing the unique challenges of recognizing and correctly classifying these diseases. He summarizes the evidence in favor of including the skin lymphomas in the overall lymphoma classification scheme and concludes with a practical description of the specific skin lymphoma entities. In Section II, Dr. Joseph Connors describes the current optimal treatment of the B-cell lymphomas when they present in or metastasize to the skin. Building on the classification scheme described by Dr. Hsi, Dr. Connors outlines a treatment approach based on current understanding of pathophysiology of these diseases and application of each of the effective modalities available for cutaneous lymphoma including radiation, chemotherapy, and immunotherapy. In Section III, Dr. Francine Foss concludes the session with a discussion of the different T-cell lymphomas that start in or spread to the skin concentrating on mycosis fungoides, cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma. She includes comments on the newer anti-T-cell chemo- and immuno-therapeutics focusing on agents and techniques specific for cutaneous T-cell lymphomas.

Peripheral T-cell lymphoma

Blood ◽  
2011 ◽  
Vol 117 (25) ◽  
pp. 6756-6767 ◽  
Author(s):  
Francine M. Foss ◽  
Pier Luigi Zinzani ◽  
Julie M. Vose ◽  
Randy D. Gascoyne ◽  
Steven T. Rosen ◽  
...  
Keyword(s):  
T Cell ◽  
Histone Deacetylase Inhibitors ◽  
Treatment Options ◽  
Proteasome Inhibitors ◽  
Treatment Strategies ◽  
Nucleoside Analogs ◽  
World Health ◽  
T Cell Lymphomas ◽  
Disease Biology ◽  
Health Organization

AbstractPeripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.

Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients

Blood ◽  
2002 ◽  
Vol 99 (3) ◽  
pp. 800-805 ◽  
Author(s):  
Regina Fink-Puches ◽  
Paulus Zenahlik ◽  
Barbara Bäck ◽  
Josef Smolle ◽  
Helmut Kerl ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Who Classification ◽  
Cell Lymphoma ◽  
World Health ◽  
European Organization ◽  
Diagnostic Categories ◽  
Cutaneous Lymphomas ◽  
Health Organization

Abstract Classification of primary cutaneous lymphomas (PCLs) is the subject of ongoing controversy. Based on a series of 556 patients, the applicability of the European Organization for Research and Treatment of Cancer (EORTC) classification for PCLs was assessed and compared to the proposed World Health Organization (WHO) classification of hematologic malignancies. The large majority of patients could be properly classified according to the scheme proposed by the EORTC. Comparison of estimated 5-year survival for specific diagnostic categories of PCLs demonstrated nearly complete concordance of the present results with those of the EORTC study for most of the indolent cutaneous T-cell lymphomas and cutaneous B-cell lymphomas, whereas differences were found for mycosis fungoides-associated follicular mucinosis and Sezary syndrome. A few patients with newly described entities (CD8+ epidermotropic cytotoxic T-cell lymphoma, primary cutaneous natural killer/T-cell lymphoma) could not be classified according to the EORTC scheme. Comparison of the EORTC with the WHO classification showed that the EORTC scheme allows a more precise categorization of the patients, especially for cutaneous B-cell lymphoma. In conclusion, the study confirmed that the EORTC classification allows a better management of patients with PCL. Small amendments to that classification should be carried out to account for recently described entities and to unify some of the diagnostic categories.

Sign in / Sign up

Export Citation Format

Share Document